Use of erythropoietin
The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
1. A method for diabetic wound healing, said method comprising administering a pharmaceutical composition comprising a subpolycythemic erythropoietin weekly dose of 1 to 90 international units (IU) EPO/kg body weight to a subject in need of said wound healing for healing of said diabetic wound.
2. The method of claim 1 , wherein the pharmaceutical composition is administered parenterally.
3. The method of claim 2 , wherein said parenteral administration is carried out using a mode selected from the group consisting of intravenous, intramuscular, intracutaneous and subcutaneous, administration.
4. The method of claim 1 , where the pharmaceutical composition is administered via pulmonary administration.
5. The method of claim 1 , wherein the pharmaceutical composition is orally administered.
6. The method of claim 1 , where the pharmaceutical composition comprises at least one further active ingredient which stimulates endothelial progenitor cells.
7. The method of claim 1 , wherein the erythropoietin is human or animal erythropoietin.